Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing
- PMID: 28470112
- PMCID: PMC5591463
- DOI: 10.2217/pgs-2017-0033
Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing
Abstract
CYP2D6 is one of the most studied enzymes in the field of pharmacogenetics. The CYP2D6 gene is highly polymorphic with over 100 catalogued star (*) alleles, and clinical CYP2D6 testing is increasingly accessible and supported by practice guidelines. However, the degree of variation at the CYP2D6 locus and homology with its pseudogenes make interrogating CYP2D6 by short-read sequencing challenging. Moreover, accurate prediction of CYP2D6 metabolizer status necessitates analysis of duplicated alleles when an increased copy number is detected. These challenges have recently been overcome by long-read CYP2D6 sequencing; however, such platforms are not widely available. This review highlights the genomic complexities of CYP2D6, current sequencing methods and the evolution of CYP2D6 from allele discovery to clinical pharmacogenetic testing.
Keywords: CYP2D6; CYP450-2D6; Sanger sequencing; genotyping; long-read sequencing; pharmacogenetics; pharmacogenomics; short-read sequencing.
Conflict of interest statement
This work was supported in part by the National Institute of General Medical Sciences (NIGMS) of the NIH, through grant K23GM104401 (SA Scott). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Figures




Similar articles
-
Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.Hum Mutat. 2016 Mar;37(3):315-23. doi: 10.1002/humu.22936. Epub 2015 Dec 18. Hum Mutat. 2016. PMID: 26602992 Free PMC article.
-
Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplications.Pharmacogenomics. 2019 Sep;20(14):1033-1047. doi: 10.2217/pgs-2019-0080. Pharmacogenomics. 2019. PMID: 31559921
-
Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.Clin Transl Sci. 2020 Jan;13(1):147-156. doi: 10.1111/cts.12695. Epub 2019 Oct 25. Clin Transl Sci. 2020. PMID: 31536170 Free PMC article.
-
Complexities of CYP2D6 gene analysis and interpretation.Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Int Rev Psychiatry. 2013. PMID: 24151800 Review.
-
Pharmacogenomic Testing in the Clinical Laboratory: Historical Progress and Future Opportunities.Ann Lab Med. 2025 May 1;45(3):247-258. doi: 10.3343/alm.2024.0652. Epub 2025 Apr 2. Ann Lab Med. 2025. PMID: 40170583 Free PMC article. Review.
Cited by
-
Role of CYP1A1, CYP2D6, and NOS3 gene polymorphisms in idiopathic recurrent pregnancy loss in the Iranian Azeri population: A case-control study.Int J Reprod Biomed. 2022 Sep 6;20(8):671-682. doi: 10.18502/ijrm.v20i8.11756. eCollection 2022 Aug. Int J Reprod Biomed. 2022. PMID: 36313260 Free PMC article.
-
CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations.Neuropsychiatr Dis Treat. 2022 Apr 2;18:731-736. doi: 10.2147/NDT.S355985. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 35401003 Free PMC article.
-
Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.J Mol Diagn. 2019 May;21(3):491-502. doi: 10.1016/j.jmoldx.2019.01.009. Epub 2019 Feb 20. J Mol Diagn. 2019. PMID: 30794985 Free PMC article.
-
Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.Medicina (Kaunas). 2019 Jul 5;55(7):344. doi: 10.3390/medicina55070344. Medicina (Kaunas). 2019. PMID: 31284530 Free PMC article.
-
The Genetic Testing Reference Materials Coordination Program: Over 10 Years of Support for Pharmacogenomic Testing.J Mol Diagn. 2023 Sep;25(9):630-633. doi: 10.1016/j.jmoldx.2023.07.001. Epub 2023 Jul 20. J Mol Diagn. 2023. PMID: 37481236 Free PMC article. No abstract available.
References
-
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013;138(1):103–141. - PubMed
-
- Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr. Med. Chem. 2009;16(21):2661–2805. - PubMed
-
- US FDA. Table of pharmacogenomic biomarkers in drug labeling. https://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics...
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical